WO2004009833A3 - Testsysteme zur auffindung von inhibitoren von inositolphosphatkinasen und verwendung dieser inhibitoren für die prophylaxe oder therapie von proliferativen erkrankungen - Google Patents

Testsysteme zur auffindung von inhibitoren von inositolphosphatkinasen und verwendung dieser inhibitoren für die prophylaxe oder therapie von proliferativen erkrankungen Download PDF

Info

Publication number
WO2004009833A3
WO2004009833A3 PCT/DE2003/002440 DE0302440W WO2004009833A3 WO 2004009833 A3 WO2004009833 A3 WO 2004009833A3 DE 0302440 W DE0302440 W DE 0302440W WO 2004009833 A3 WO2004009833 A3 WO 2004009833A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
prophylaxis
proliferative diseases
therapy
gene
Prior art date
Application number
PCT/DE2003/002440
Other languages
English (en)
French (fr)
Other versions
WO2004009833A2 (de
Inventor
Georg W Mayr
Marcus M Nalaskowski
Kirsten Hillemeier
Original Assignee
Medlnnova Ges Fuer Medizinisch
Georg W Mayr
Marcus M Nalaskowski
Kirsten Hillemeier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medlnnova Ges Fuer Medizinisch, Georg W Mayr, Marcus M Nalaskowski, Kirsten Hillemeier filed Critical Medlnnova Ges Fuer Medizinisch
Priority to AU2003254631A priority Critical patent/AU2003254631A1/en
Publication of WO2004009833A2 publication Critical patent/WO2004009833A2/de
Publication of WO2004009833A3 publication Critical patent/WO2004009833A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Die Erfindung betrifft die Verwendung einer IP3K und/oder einer IPMK, bevorzugt des Menschen oder des höheren Vertebraten für ein Testsystem mit einer IP3K und/oder einer IPMK zur Auffindung von Wirkstoffen zur Prophylaxe und Therapie pro­liferativer Erkrankungen. Die Erfindung betrifft des Weiteren ein neues humanes Gen, Verwendungen dieses Gens in Screening Verfahren, ein Testsystem mit diesem Gen und Verwendungen verschiedener Substanzen zur Hemmung dieses Gens oder seines Genprodukts.
PCT/DE2003/002440 2002-07-16 2003-07-16 Testsysteme zur auffindung von inhibitoren von inositolphosphatkinasen und verwendung dieser inhibitoren für die prophylaxe oder therapie von proliferativen erkrankungen WO2004009833A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003254631A AU2003254631A1 (en) 2002-07-16 2003-07-16 Test systems for detecting inhibitors of inositol phosphate kinases and use of these inhibitors for the prophylaxis or therapy of proliferative diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2002132723 DE10232723A1 (de) 2002-07-16 2002-07-16 Testsystem zur Auffindung von Inhibitoren von Inositolphosphatkinasen und Verwendungen dieser Inhibitoren für die Prophylaxe oder Therapie von proliferativen Erkrankungen
DE10232723.8 2002-07-16

Publications (2)

Publication Number Publication Date
WO2004009833A2 WO2004009833A2 (de) 2004-01-29
WO2004009833A3 true WO2004009833A3 (de) 2004-12-02

Family

ID=30010184

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2003/002440 WO2004009833A2 (de) 2002-07-16 2003-07-16 Testsysteme zur auffindung von inhibitoren von inositolphosphatkinasen und verwendung dieser inhibitoren für die prophylaxe oder therapie von proliferativen erkrankungen

Country Status (3)

Country Link
AU (1) AU2003254631A1 (de)
DE (1) DE10232723A1 (de)
WO (1) WO2004009833A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004066926A2 (en) * 2003-01-25 2004-08-12 Irm Llc Methods and compositions for modulating t lymphocytes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0702087A1 (de) * 1994-09-14 1996-03-20 Landesvereinigung der Bayerischen Milchwirtschaft e.V. Testmedium für einen mikrobiologischen Hemmstofftest und Verfahren zu seiner Durchführung
WO1997046688A1 (en) * 1996-06-01 1997-12-11 Ludwig Institute For Cancer Research Lipid kinase
US6100090A (en) * 1999-06-25 2000-08-08 Isis Pharmaceuticals Inc. Antisense inhibition of PI3K p85 expression

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648214A (en) * 1990-06-11 1997-07-15 University Research Corporation High-affinity oligonucleotide ligands to the tachykinin substance P
US5385936A (en) * 1990-07-12 1995-01-31 The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services Gossypol acetic acid for the treatment of cancer
DE69103503T2 (de) * 1990-09-28 1995-01-05 Mercian Corp Adriamycinderivate.
CA2330790A1 (en) * 1998-05-04 1999-11-11 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Method and device for isolating nucleic acids
DE19819889A1 (de) * 1998-05-04 1999-11-11 Fraunhofer Ges Forschung Verfahren zur Isolierung von Nucleinsäuren
DE19837758A1 (de) * 1998-08-20 2000-02-24 Beiersdorf Ag Verwendung von Wirkstoffkombinationen aus Flavonoiden und UV-Filtersubstanzen als antivirales Wirkprinzip
KR20000019718A (ko) * 1998-09-15 2000-04-15 박호군 탄닌 또는 탄닌 유래 페놀성 화합물을 포함하는 동맥경화증, 고지혈증 및 간질환의 예방 및 치료용 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0702087A1 (de) * 1994-09-14 1996-03-20 Landesvereinigung der Bayerischen Milchwirtschaft e.V. Testmedium für einen mikrobiologischen Hemmstofftest und Verfahren zu seiner Durchführung
WO1997046688A1 (en) * 1996-06-01 1997-12-11 Ludwig Institute For Cancer Research Lipid kinase
US6100090A (en) * 1999-06-25 2000-08-08 Isis Pharmaceuticals Inc. Antisense inhibition of PI3K p85 expression

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBI 14 January 2000 (2000-01-14), "Homo sapiens chromosome 19 clone LLNLR-244B2, complete sequence", XP002290628, retrieved from EBI Database accession no. AC020950 *
DATABASE EMBL 13 November 2001 (2001-11-13), STRAUSBERG R. ET AL.: "Homo sapiens, clone IMAGE:4510867, mRNA", XP002290627, retrieved from EBI Database accession no. BC016612 *
DATABASE EMBL 7 September 2001 (2001-09-07), TANG Y.T. ET AL.: "Human polypeptide SEQ ID NO: 20977 of patent WO200164835", XP002290626, retrieved from EBI Database accession no. AAO07085 *
SAIARDI A. ET AL.: "Inositol polyphosphate multikinase (ArgRIII) determines nuclear mRNA export in Saccharomyces cerevisiae", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 468, no. 1, 18 February 2000 (2000-02-18), pages 28 - 32, XP004260992, ISSN: 0014-5793 *
SAIARDI A. ET AL.: "Mammalian inositol polyphosphate multikinase synthesizes inositol 1,4,5-trisphosphate and an inositol pyrophosphate", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 98, no. 5, 27 February 2001 (2001-02-27), pages 2306 - 2311, XP002290624, ISSN: 0027-8424 *
SAIARDI A. ET AL.: "Synthesis of diphosphoinositol pentakisphosphate by a newly identified family of higher inositol polyphosphate kinases", CURRENT BIOLOGY, vol. 9, no. 22, 18 November 1999 (1999-11-18), pages 1323 - 1326, XP002290625, ISSN: 0960-9822 *
SEDLACEK H.H.: "Kinase inhibitors in cancer therapy: A look ahead", DRUGS, vol. 59, no. 3, March 2000 (2000-03-01), pages 435 - 476, XP009034095, ISSN: 0012-6667 *
SHEARS S.B.: "The versatility of inositol phosphates as cellular signals", BIOCHIMICA AND BIOPHYSICA ACTA. MOLECULAR AND CELL BIOLOGY OF LIPIDS, ELSEVIER, AMSTERDAM, NL, vol. 1436, no. 1-2, 8 December 1998 (1998-12-08), pages 49 - 67, XP004277217, ISSN: 1388-1981 *

Also Published As

Publication number Publication date
DE10232723A1 (de) 2004-02-05
AU2003254631A1 (en) 2004-02-09
WO2004009833A2 (de) 2004-01-29
AU2003254631A8 (en) 2004-02-09

Similar Documents

Publication Publication Date Title
WO2006069080A3 (en) Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2m3-b]pyrimidin-4-yl-amines as janus kinase inhibitors
EP2612862A3 (de) Quinazolinone als Inhibitoren der humanen Phosphatidylinosit-3-Kinase Delta
WO2008080134A3 (en) 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
WO2009064802A3 (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta
WO2004047755A3 (en) Fused bicyclic nitrogen-containing heterocycles
MXPA06001134A (es) Inhibidores de la actividad de la proteina cinasa b.
MX346183B (es) Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas heteroarilo-sustituidas como inhibidores de cinasas janus.
WO2007058850A3 (en) Inhibitors of akt activity
WO2007044441A3 (en) Use of pyrazolo [1 , 5 -a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases
EP1140840A4 (de) -g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren
WO2003073999A3 (en) Pini-modulating compounds and methods of use thereof
UA104849C2 (uk) 4-піразоліл-n-арилпіримідин-2-аміни і 4-піразоліл-n-гетероарилпіримідин-2-аміни як інгібітори кіназ janus
WO2007030680A3 (en) Triazole derivatives useful as axl inhibitors
WO2007058942A3 (en) Imidazopyrazines as protein kinase inhibitors
WO2011046964A3 (en) Inhibitors of bruton's tyrosine kinase
WO2003074550A3 (en) Pin1-modulating compounds and methods of use thereof
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
WO2006113837A3 (en) Inhibitors of akt activity
WO2003051302A3 (en) Methods and compositions for treatment of central nervous system disorders
HK1079220A1 (en) Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases cd83
AU2003256203A1 (en) Alpha-7 nicotinic receptor agonists and statins in combination
WO2004084943A8 (en) Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
TW200505443A (en) Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
WO2007023310A3 (en) Stimulation of neurogenesis with help of alk inhibitors
WO2004033666A3 (en) Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP